多种生物标志物算法预测盆腔包块女性上皮性卵巢癌:增加标志物能否改善效能?
本研究为经伦理审查委员会批准的前瞻性临床试验,检测盆腔包块且随后接受手术女性的血清CA125、HE4、YKL-40、转甲状腺素蛋白、载脂蛋白A1、β2微球蛋白、转铁蛋白和溶血磷脂酸水平,用逻辑回归与ROC曲线评估各标志物组合。184例中HE4联合CA125(即ROMA)检测上皮性卵巢癌与良性疾病的AUC为91.2%(95%CI 86.0-96.4);八项标志物联合绝经状态的组合AUC最高为94.6%(95%CI 90.1-99.2),但与HE4联合CA125相比无显著差异(P=0.078)。结论是增加所选血清标志物并未提升双标志物组合的检测效能。
要点
- HE4联合CA125(ROMA)检测上皮性卵巢癌与良性疾病的AUC为91.2%(95%CI 86.0-96.4)。
- 八项标志物联合绝经状态的组合AUC为94.6%(95%CI 90.1-99.2),与双标志物组合无显著差异(P=0.078)。
- 在HE4与CA125基础上增加所选血清标志物未提升卵巢癌检测效能。
核心结论
- 在HE4与CA125基础上增加所选进一步血清标志物,并未提升双标志物组合检测卵巢癌的效能。
研究设计与样本
- 经伦理审查委员会批准的前瞻性临床试验,检测盆腔包块且随后接受手术女性的血清标志物,共184例符合纳入标准,中位年龄56岁(范围20-91)。
主要发现
- 最终病理为良性肿瘤103例(56.0%)、交界性(LMP)肿瘤4例(2.2%)、上皮性卵巢癌61例(33.1%)、非上皮性卵巢癌2例(1.1%)、妇科癌卵巢转移6例(3.3%)、非妇科癌卵巢转移8例(4.3%)。
- HE4联合CA125(即ROMA)检测上皮性卵巢癌与良性疾病的AUC为91.2%(95%CI 86.0-96.4)。
- CA125、HE4、YKL-40、转甲状腺素蛋白、载脂蛋白A1、β2微球蛋白、转铁蛋白、溶血磷脂酸联合绝经状态的组合AUC最高,为94.6%(95%CI 90.1-99.2)。
- 上述八项标志物联合绝经状态的组合与单用HE4联合CA125相比无显著差异(P=0.078)。
临床怎么用
- 原文未据此给出推荐,结论为在HE4与CA125基础上增加所选血清标志物未提升双标志物组合检测卵巢癌的效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Management of a woman with a pelvic mass is complicated by difficulty in discriminating malignant from benign disease. Many serum biomarkers have been examined to determine their sensitivity for detecting malignancy. This study was designed to evaluate if the addition of biomarkers to HE4 and CA125, as used in the Risk of Malignancy Algorithm (ROMA), can improve the detection of EOC. METHODS: This was an IRB approved, prospective clinical trial examining serum obtained from women diagnosed with a pelvic mass who subsequently underwent surgery. Serum biomarker levels for CA125, HE4, YKL-40, transthyretin, ApoA1, Beta-2-microglobulin, transferrin, and LPA were measured. Logistic regression analysis was performed for various marker combinations, ROC curves were generated, and the area under the curves (AUCs) were determined. RESULTS: A total of 184 patients met inclusion criteria with a median age of 56 years (Range 20-91). Final pathology revealed there were 103 (56.0%) benign tumors, 4 (2.2%) LMP tumors, 61 EOC (33.1%), 2 (1.1%) non-EOC ovarian cancers, 6 (3.3%) gynecologic cancers with metastasis to the ovary and 8 (4.3%) non-gynecologic cancers with metastasis to the ovary. The combination of HE4 and CA125 (i.e. ROMA) achieved an AUC of 91.2% (95% CI: 86.0-96.4) for the detection of EOC vs benign disease. The combination of CA125, HE4, YKL-40, transthyretin, ApoA1, Beta 2 microglobulin, transferrin, LPA and menopausal status achieved the highest AUC of 94.6% (95% CI: 90.1-99.2) but this combination was not significantly better than the HE4 and CA125 combination alone (p = 0.078). CONCLUSIONS: The addition of select further serum biomarkers to HE4 and CA125 does not add to the performance of the dual marker combination for the detection of ovarian cancer.
引用
- Moore RG, Blackman A, Miller MC, et al. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance? Gynecol Oncol. 2019. PMID: 30992143. doi:10.1016/j.ygyno.2019.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。